MaxCyte (LON:MXCT) Shares Up 3.4% - Here's Why

MaxCyte, Inc. (LON:MXCT - Get Free Report) traded up 3.4% on Thursday . The stock traded as high as GBX 340 ($4.29) and last traded at GBX 335 ($4.23). 12,456 shares traded hands during trading, a decline of 60% from the average session volume of 30,823 shares. The stock had previously closed at GBX 324 ($4.09).

MaxCyte Trading Down 0.3 %

The company has a current ratio of 14.31, a quick ratio of 14.38 and a debt-to-equity ratio of 8.37. The stock has a market capitalization of £351.00 million, a price-to-earnings ratio of -1,292.31 and a beta of 1.13. The business has a 50 day simple moving average of GBX 283.88 and a 200-day simple moving average of GBX 315.26.

Insider Transactions at MaxCyte

In related news, insider Stan Erck sold 47,689 shares of MaxCyte stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of GBX 388 ($4.90), for a total value of £185,033.32 ($233,539.47). Insiders own 1.45% of the company's stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.